GLP-1 Makers Test New Routes to Patients

Drugmakers expand cash-pay and digital channels as competition shifts from clinical results to access and demand control

19 Feb 2026

Drugmakers competing in the fast-growing market for GLP-1 weight-loss and diabetes treatments are shifting their focus from clinical performance to patient access, expanding direct-to-consumer channels that sit outside traditional insurance systems.

Eli Lilly and Novo Nordisk have introduced manufacturer-backed online platforms that allow patients to complete telehealth consultations, obtain prescriptions and arrange home delivery. The services, which typically operate on a cash-pay basis, were initially designed to address gaps in insurance coverage and reimbursement delays. They are now evolving into a broader experiment in market access.

The new channels do not replace established pharmacy and insurer networks, but run alongside them. For patients facing high out-of-pocket costs or administrative barriers, the appeal lies in clearer pricing and faster processing. Companies present the platforms as a way to simplify access while maintaining existing distribution partnerships.

The strategy has wider commercial implications. By interacting directly with patients, manufacturers gain closer insight into prescribing behaviour, adherence rates and regional demand. Such information is increasingly valuable as companies invest heavily in expanding production capacity for injectable GLP-1 drugs, which have faced periodic shortages.

Better visibility over demand could improve production planning and reduce volatility. Some companies are also exploring subscription-style pricing through digital platforms, which may help stabilise revenue and smooth purchasing patterns in a market marked by rapid growth.

The approach is not without risks. Regulators continue to monitor online prescribing practices, particularly for high-demand medicines. Healthcare providers have raised concerns about care coordination if patients rely primarily on digital-only services. Any renewed supply disruption could also undermine consumer confidence in direct channels.

For now, manufacturer-led platforms remain limited in scale. But their expansion reflects a broader reassessment of how specialty medicines are distributed. As the GLP-1 market enters a new phase of growth, competition is likely to hinge not only on clinical data but also on pricing transparency, digital engagement and control over supply chains.